Zynex (ZYXI) to Release Earnings on Wednesday

Zynex (NASDAQ:ZYXI - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Wednesday, July 23rd. Analysts expect Zynex to post earnings of ($0.20) per share and revenue of $27.38 million for the quarter.

Zynex (NASDAQ:ZYXI - Get Free Report) last issued its quarterly earnings data on Monday, April 28th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.09). Zynex had a negative return on equity of 23.70% and a negative net margin of 4.30%. The company had revenue of $26.58 million for the quarter, compared to the consensus estimate of $30.83 million. On average, analysts expect Zynex to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zynex Trading Down 1.7%

NASDAQ ZYXI traded down $0.04 during trading hours on Friday, hitting $2.31. 70,109 shares of the company's stock were exchanged, compared to its average volume of 174,382. The stock has a 50-day simple moving average of $2.33 and a 200 day simple moving average of $4.19. Zynex has a 1-year low of $1.66 and a 1-year high of $10.47. The firm has a market cap of $69.85 million, a price-to-earnings ratio of -9.62 and a beta of 0.83. The company has a current ratio of 3.46, a quick ratio of 2.63 and a debt-to-equity ratio of 2.87.

Hedge Funds Weigh In On Zynex

An institutional investor recently raised its position in Zynex stock. Goldman Sachs Group Inc. increased its stake in Zynex Inc. (NASDAQ:ZYXI - Free Report) by 118.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 170,718 shares of the company's stock after acquiring an additional 92,463 shares during the period. Goldman Sachs Group Inc. owned about 0.56% of Zynex worth $376,000 as of its most recent SEC filing. 29.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ZYXI has been the subject of a number of research reports. Royal Bank Of Canada reduced their price objective on Zynex from $4.00 to $3.00 and set a "sector perform" rating for the company in a research note on Tuesday. HC Wainwright reissued a "buy" rating and issued a $8.00 price objective on shares of Zynex in a research note on Monday, June 30th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.